Global Expansion Curium’s plan to expand into Japan and China through its oncology-focused nuclear medicine strategy creates opportunities for market-entry partnerships, regional distribution agreements, and regulatory co-development with local partners to accelerate patient access.

Lu-177 Capacity The €32 million Saclay production line for Lu-177-PSMA-I&T indicates scalable radiopharmaceutical manufacturing capabilities, enabling potential long-term contracted supply, contract manufacturing, and equipment/service partnerships for next-generation radioligand therapies.

NETs and PSMA A focused portfolio on Neuroendocrine Tumors and PSMA therapy offers cross-selling of diagnostic radiopharmaceuticals and therapeutic agents, plus collaboration on clinical trials, data sharing, and pathways to integrate imaging with therapy for oncology programs.

AI Imaging Curium’s investment in AI to improve image quality and diagnostic accuracy presents a sales angle for selling AI-enabled image analysis tools, reconstruction software, and data analytics services aligned with radiopharmaceutical imaging workflows.

Reliable Partner With a strong heritage of reliable radiopharmaceutical solutions serving tens of thousands of patients, Curium offers opportunities for strategic supply chain partnerships, logistics optimization, and long-term service and maintenance agreements across hospital networks.